))
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
Manage episode 364434400 series 3381831
Content provided by MPR Weekly Dose. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MPR Weekly Dose or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.
207 episodes
Share
